Clinical trial registry record

Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 6, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05941715
Last registry update
June 6, 2025
Status
Completed
Phase
Phase 4
Sponsor
Medical University of Graz
Enrollment
70
Countries
Austria
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
70
Population
ALL · 50 Years
Duration
2023-07-04 to 2025-02-26
Intervention
Aflibercept 40 MG/ML; Faricimab 120 MG/ML
Comparator
group A: aflibercept first (part 1), switch to faricimab (part 2)
Outcomes measured
Proportion of eyes with at least one extension without retinal (intra- and subretinal) fluid within the time period bas…; Proportion of eyes with maximum extended interval without retinal (intra- and subretinal) fluid of ≥ 6, ≥ 8, ≥ 10 weeks…; Maximum extended treatment interval without retinal (intra- and subretinal) fluid — at 32 weeks and 56 weeks; Number of injections received — during 32 weeks and 1 year; Proportion of eyes remaining on a 4-weekly interval from baseline to last visit (completed interval) — at 32 weeks and…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON